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Abstract: The global spread of severe acute respiratory syndrome coronavirus 2, which causes coron-
avirus disease 2019 (COVID-19), could be due to limited access to diagnostic tests and equipment.
Currently, most diagnoses use the reverse transcription polymerase chain reaction (RT-PCR) and
chest computed tomography (CT). However, challenges exist with CT use due to infection control,
lack of CT availability in low- and middle-income countries, and low RT-PCR sensitivity. Passive
microwave radiometry (MWR), a cheap, non-radioactive, and portable technology, has been used for
cancer and other diseases’ diagnoses. Here, we tested MWR use first time for the early diagnosis of
pulmonary COVID-19 complications in a cross-sectional controlled trial in order to evaluate MWR
use in hospitalized patients with COVID-19 pneumonia and healthy individuals. We measured the
skin and internal temperature using 30 points identified on the body, for both lungs. Pneumonia and
lung damage were diagnosed by both CT scan and doctors’ diagnoses (pneumonia+/pneumonia−).
COVID-19 was determined by RT-PCR (covid+/covid−). The best MWR results were obtained for
the pneumonia−/covid− and pneumonia+/covid+ groups. The study suggests that MWR could be
used for diagnosing pneumonia in COVID-19 patients. Since MWR is inexpensive, its use will ease
the financial burden for both patients and countries. Clinical Trial Number: NCT04568525.
Keywords: COVID-19; passive microwave radiometry (MWR); infrared radiometry (IR); RT-PCR; CT
1. Introduction
A significant number of deaths occur in coronavirus disease 2019 (COVID-19) patients
with multiple concomitant diseases around the world, such as interstitial pneumonia, acute
respiratory distress syndrome, and subsequent multiple organ failure [1]. Severe lung
damage has been reported at any age. In infected persons, various degrees of pneumonia
and radiological signs are observed [2,3]. Currently, most research are focused on the use
of computed tomography (CT) to identify the chest manifestations of COVID-19 [4,5]. In
contrast to the high chest CT sensitivity, the specificity is relatively low (approximately
25–33%). There are obstacles to using CT due to the need for infection control related to
patient transportation, need for disinfection of CT rooms after patient examination, and
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the lack of accessibility to the CT equipment [6]. In the early stage of disease progression,
ground-glass opacities are the predominant lesions. In the next stage, crazy paving patterns
highlights the inflammatory changes. The peak stage is marked by fibrosis and diffuse
damage. These CT lesions are also observed in other pneumonia and non-infectious
inflammatory lung diseases, but in a pandemic context, CT shows diagnostic potential for
COVID-19, especially for patient triage [7–9].
In healthcare settings with limited polymerase chain reaction (PCR) capacity and long
turnaround times, chest CT is proposed as an alternative for COVID-19 diagnosis. Studies
supporting chest CT as a first-line diagnostic tool for COVID-19 have revealed several
methodological concerns [10–12]. There are associated costs and procedural risks with
CT [13–15].
The other method for diagnosing COVID-19, reverse transcription PCR (RT-PCR), has
a variable sensitivity as low as 70% [16]. The specificity of viral swabs in clinical practice
varies depending on the site and quality of sampling. In one study, the RT-PCR sensitivity
in 205 patients varied, at 93% for bronchoalveolar lavage, 72% for sputum, 63% for nasal
swabs, and only 32% for throat swabs [17]. The test results are also likely to vary depending
on the stage and degree of viral load or clearance [17,18]. The use of repeat RT-PCR testing
as a standard is likely to address the probably low specificity as well as the true rate of false
negatives, because not all patients receive repeat testing results. Therefore, another safer
and inexpensive method is required to replace and/or compliment CT and PCR tests.
Microwave radiometry (MWR) technology [19] has already been used for the early
diagnosis of cancer and other diseases. It measures emission in the microwave range
of tissues/organs to a depth of 5 cm beneath the skin. Increased microwave emission
could result from inflammation, while decreased emission could be due to fibrosis. The
advantage of MWR is that the temperature manifestations can be revealed before any
structural changes can be registered.
During the 1980s–1990s, there were several studies on the identification of excess
microwave emission due to fluid in the lungs (on phantoms), which could be an indication
of inflammatory processes, pneumonia, cancer, and other lung disorders [20,21]. Later,
clinical studies confirmed the results for lung cancer [22,23].
The purpose of this study was to investigate the value of MWR and compare mi-
crowave (internal temperature) and infrared emissions (skin temperature) from the left and
right lungs with those of chest CT and RT-PCR to determine the diagnostic performance of
MWR in individuals with COVID-19 symptoms.
2. Materials and Methods
In this trial (Kyrgyz Committee Clinical Trial Number: 01-2/141; 27 May 2020), from 1
June 2020 to 1 August 2020, we performed parallel MWR, PCR, and CT tests for individuals
with COVID-19 admitted to the hospital for medical emergencies related to COVID-19
with suspected pneumonia. CT scans were performed with a Siemens Ecoline CT scanner
(Munich, Germany) and as described in a standard routine by a hospital physician who was
not directly involved in this research. RT-PCR was performed using “DNA technology” kits
(DNA-Technology LLC, Moscow, Russia). For the MWR and infrared (IR) measurements,
MWR2020 (RTM-01-RES) (Figure 1) was used (MMWR LTD, Edinburgh, UK). It is a unique
commercial CE-marked device registered in the UK MHRA MDN 40802 (Freepost Yellow
Card scheme-MHRA, London, UK) as a microwave thermography system for clinical
studies. The device is already registered in Kyrgyzstan for breast cancer diagnosis. The
technical parameters are in Table 1.
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This is an analysis of a single-center prospective trial on consecutive individuals ad-
mitted to the Medical Center of Kyrgyz State Medical Academy (KSMA) BICARD clinic 
from 1 July 2020 to 1 August 2020. KSMA is a central-network regional hospital that pro-
vides tertiary healthcare for a community of 500,000 inhabitants. All individuals admitted 
to the hospital on the clinical suspicion of COVID-19 pneumonia (confirmed by experi-
enced pulmonologists, so that symptomatic individuals were the inclusion criteria) re-
ceived a combined screening using chest CT and RT-PCR. We used COVID-19 case defi-
nition as specified in the World Health Organization (WHO) document [24] for classifying 
symptomatic individuals. Patients with lung comorbidity and individuals without 
COVID-19 symptoms did not receive chest CT. Exclusion criteria included lung comor-
bidity (such as exacerbation of chronic obstructive pulmonary disease (COPD) and very 
severe COPD with hypoxia (FEV1 < 40%, saturation < 92% at an altitude of 760 m)), comor-
bidities (such as cardiovascular diseases, including unstable systemic arterial hyperten-
sion, coronary heart disease, stroke, sleep apnea, pneumothorax lasting past two months, 
neurological, rheumatological, or psychiatric illnesses), excessive smoking (>20 cigarettes 
per day), and kidney failure. 
The study NCT04568525 was approved on 27.02.2020 by the Kyrgyz Republic Review 
Board, and informed consent was obtained from all the subjects. Overall, we measured 
internal (MWR) and skin (IR) temperatures in 208 subjects (84 males and 124 females) 
aged 18 to 75 years old. A total of 135 patients were hospitalized with pneumonia symp-
toms in KSMA Medical Center and the BICARD clinic, Bishkek, while 73 subjects were 
selected from healthy volunteers with no COVID-19 and pneumonia symptoms. RT-PCR 
was performed for each hospitalized subject, and 112 subjects were found to be positive 
for COVID-19 using RT-PCR test. 
Healthy volunteers with no COVID-19 and pneumonia symptoms did not receive 
chest CT, but they were tested using MWR. Body mass index (BMI), auxiliary (armpit) 
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Table 1. Technical specification.
Key Features (MWR2020)
Temperature detection depth, cm 3–7
Accuracy of internal temperature measurements (microwave range), ◦C 0.2
Measurement time, s 8
Antenna diameter, mm 39
Accuracy of skin temperatu e measur ments (infrared range), ◦C 0.2
Weight, kg 2.5
Power, W 20
This is an analysis of a single-center prospective trial on consecutive individuals admit-
ted to the Medical Center of Kyrgyz State Medical Academy (KSMA) BICARD clinic from
1 July 2020 to 1 August 2020. KSMA is a central-network regional hospital that provides
tertiary healthcare for a community of 500,000 inhabitants. All individuals admitted to
the hospital on the clinical suspicion of COVID-19 pneumonia (confirmed by experienced
pulmonologists, so that symptomatic individuals were the inclusion criteria) received a
combined screening using chest CT and RT-PCR. We used COVID-19 case definition as
specified in the World Health Organization (WHO) document [24] for classifying symp-
tomatic individuals. Patients with lung comorbidity and individuals without COVID-19
symptoms did not receive chest CT. Exclusion criteria included lung comorbidity (such
as exacerbation of chronic obstructive pulmonary disease (COPD) and very severe COPD
with hypoxia (FEV1 < 40%, saturation < 92% at an altitude of 760 m)), comorbidities (such
as cardiovascular diseases, including unstable systemic arterial hypertension, coronary
heart disease, stroke, sleep apnea, pneumothorax lasting past two months, neurological,
rheumatological, or psychiatric illnesses), excessive smoking (>20 cigarettes per day), and
kidney failure.
The study NCT04568525 was approved on 27.02.2020 by the Kyrgyz Republic Review
Board, and informed consent was obtained from all the subjects. Overall, we measured
internal (MWR) and skin (IR) temperatures in 208 subjects (84 males and 124 females) aged
18 to 75 years old. A total of 135 patients were hospitalized with pneumonia symptoms in
KSMA Medical Center and the BICARD clinic, Bishkek, while 73 subjects were selected
from healthy volunteers with no COVID-19 and pneumonia symptoms. RT-PCR was
performed for each hospitalized subject, and 112 subjects were found to be positive for
COVID-19 using RT-PCR test.
Healthy volunteers with no COVID-19 and pneumonia symptoms did not receive
chest CT, but they were tested using MWR. Body mass index (BMI), auxiliary (armpit) tem-
perature, and SpO2 were additionally assessed as part of the hospital admission routines.
As there were no previous measurements of the lungs using MWR, a new measure-
ment technique was design d for this research. Thirty points were identified on the body,
28 symmetrical (R1-R14, –L1-L14) and 2 ontrols (T1 and T2), as shown in Figures 2–4.
The software application “RTM Diagnosis 1.79” was configured to perform these mea-
surements, record the temperatures, and plot the corresponding temperature fields. The
measuremen of a single point takes no more than 10 s, and thus the overall measurement
cycle is approximately 5 min. The existing measurement technique, for example, for the
breast, requires a cloth-off condition. However, it is not very practical and leads to patient
Diagnostics 2021, 11, 259 4 of 15
discomfort. To assess the possibility of measurements with the clothes on, we measured 83
subjects through thin clothes and 125 with the clothes off.
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3.2. Clinical Images
Figure 6 shows the typical MWR image of COVID-19 pneumonia. On both the left
and right lungs, there are a large internal temperature difference in the blue areas (low
temperature, due to fibrosis) and red areas (high temperature, due to inflammation).
Figure 7 shows the lungs of healthy individuals, while Figure 8 depicts no COVID-19
pneumonia, where only the regions of inflammations could be observed, but no blue zones
are visible.
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3.3. Statistical Results
We measured four temperature values: Tint,R, Tint,L, Tsk,R, Tsk,L at 14 symmetrical
points on the body (right, left) and two asymmetrical points.
From existing microwave diagnostic practice, point temperature values are usually not
i formative du to individual human tissue variance; however, patterns are being formed.
Therefore, we hypothesized that
1. The difference in symmetrical points should be less than 0.5 ◦C in healthy patients
and be of grea er value in patients with pneumonia;
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2. The difference between internal and skin temperatures should be uniform in healthy
patients but might show local abnormalities in patients with pneumonia;
3. The difference between the hottest and coldest points should be less than 2 ◦C in
healthy patients.
We introduced 16 aggregated metrics, each of which was calculated pointwise. The
median was preferred over a simple mean intentionally in order to reduce the effect of
poorly performed measurements.




• Median asymmetry (#1) shows the overall disbalance between the left and right sides;
the standard deviation of asymmetry (#5) aggregates the local irregularities, while the
maximum asymmetry highlights the asymmetry at a single point (#9).
• Asymmetry inverse (ASIN) (#2) reveals the condition when the internal and skin
temperatures show asymmetry with significantly different magnitudes or signs.∣∣(Tint,R − Tint,L)− (Tsk,R − Tsk,L)∣∣
ASIN shows the overall equality between internal and skin asymmetry; ASIN max
(#10) shows the irregularity at a single point.
• Spread (SP) expresses the difference between the internal and skin temperatures.
Tint,R − Tsk,R + Tint,L − Tsk,L
• SP median (#3) shows the overall change, which is caused by the systematic changes
in the metabolism or thermal properties; SP std (#7) shows the non-uniformity of the
internal-skin difference; SP max (#11) highlights the anomaly at a single point.
• Relative increase (RI) aimed to reveal the irregular points of increase or decrease. It
is calculated as the value of the difference between the internal value and the median
of all internal values for that patient{
Tint,R −med(Tint), i f |Tint,R −med(Tint)| > |Tint,L −med(Tint)|
Tint,L −med(Tint), otherwise
RI median (#4) indicates the overall tendency of increase or decrease over the baseline
uniform distribution, and RI max (#12) shows the hottest position.
• Internal median (#13) shows a shift in the baseline level of the internal temperature.
• Internal percentile interval (#14) (5–95%) is aimed at measuring the spread between
the hottest and coldest measured points. The same applies for the skin (#15, #16).
Each metric was separately tested to show statistically significant differences between
the four groups: (covid+/pneumonia+), (covid−/pneumonia−), (covid+/pneumonia−),
and (covid−/pneumonia+).
Then, we used the one-way multi-group analysis of variance (ANOVA) (Table 3)
to check for similarities in means between the four groups. For metrics with p < 0.05,
pairwise Tukey test (Table 3) was performed to assess differences in metrics between groups’
pairwise. Pairs are meant to be significant if p < 0.05 in Tukey test. These assessments were
performed using Python script [27–29].
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(p < 0.05) f-Value p-Value Reject Null-Hyp (p < 0.05)
1. AS median 0.34 0.79 No 3.21 0.03 Yes
2. ASIN median 0.05 0.98 No 3.08 0.03 Yes
3. SP median 3.65 0.02 Yes 12.35 4.18 × 107 Yes
4. RI median 0.81 0.49 No 2.90 0.04 Yes
5. AS std 0.30 0.82 No 0.05 0.98 No
6. ASIN std 0.58 0.62 No 1.32 0.27 No
7. SP std 0.30 0.83 No 2.73 0.05 Yes
8. RI std 0.32 0.81 No 0.11 0.96 No
9. AS max 0.24 0.86 No 0.05 0.99 No
10. ASIN max 0.67 0.57 No 1.05 0.37 No
11. SP max 0.08 0.97 No 5.67 1.1 × 103 Yes
12. RI max 0.71 0.55 No 1.12 0.34 No
13. Int median 2.54 0.06 No 2.88 0.039 Yes
14. Sk median 7.26 2.2 × 104 Yes 6.09 6.7 × 104 Yes
15. Int interval 3.16 0.03 Yes 0.22 0.87 No
16. Sk interval 0.93 0.42 No 0.36 0.77 No
The pairwise Tukey test (Table 4) shows that the border groups (covid−/pneumonia−)
and (covid+/pneumonia+) differed in almost all the relevant features. COVID-19 patients
were characterized by an increase in internal temperature (+1.3 ◦C) and decrease in skin
temperature (−0.6 ◦C), and consequently, increase in the spread between the internal and
skin (median from +1.48 ◦C, up to +2.7 ◦C at single points).
Table 4. Significant pairs.
Criteria Significant Pairs (Clothes on) Significant Pairs (Clothes off)
SP median Covid− pneumonia−/covid+pneumonia+ (delta = +1.1, p = 0.0075)
Covid− pneumonia−/covid+ pneumonia+ (delta = +1.48,
p < 0.001)
SP std Covid− pneumonia−/covid+ pneumonia+ (delta = +0.40,p = 0.025)
SP max Covid− pneumonia−/covid+ pneumonia+ (delta = +2.72,p < 0.001)
Int median Covid− pneumonia−/covid+ pneumonia− (delta = +1.31,p = 0.043)
Sk median
Covid− pneumonia−/covid+
pneumonia+ (delta = −1.00, p = 0.001)
Covid− pneumonia+/covid+
pneumonia+ (delta = −0.85, p = 0.008)
Covid− pneumonia−/covid+ pneumonia+ (delta = −0.64,
p = 0.008)
Covid− pneumonia+/covid+ pneumonia− (delta = +3.12,
p = 0.006)
The analysis showed that groups measured with clothes off had more pronounced
differences than those measured with clothes on. For the groups with clothes on, covid+/
pneumonia+ patients had their median skin temperatures lowered by 1.0 ◦C with identical
internal temperatures. It is important to combine the internal and skin temperatures to
estimate and determine the significant differences between the four groups. We originally
hypothesized that absolute temperature values will be least informative, but we found
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that the greatest effect was a decrease in the absolute value of the skin temperature and
an increase in the spread (SP). Asymmetries showed no change. This might be explained
mostly by the bilateral cases of COVID-19 pneumonia.
On the basis of the statistical results, for subsequent AI analysis, we decided to com-
bine the clothes on/off groups together and train the network using the most informative
aggregated metrics along with the raw temperature data.
3.4. Deep Neural Network Results
We used as a starting model the same deep neural network (DNN) we have earlier
applied for breast cancer diagnostics [30–32]. For this iteration, we further improved the
dense model by incorporating characteristics from the Cascade Correlation Neural Network
(CCNN). This includes the addition of skip connections and an increased number of hidden
layers in the model. Each layer has as input the original input points and the output of
all previous layers, which is aggregated by concatenation. Additionally, regularization
techniques have been included to avoid early overfitting, such as random node dropout,
Gaussian noise, and L1/L2 weight regularizers.
Thus, it allows the model to identify both shallow and deep metrics in the training set.
In addition, it overcomes some of the limitations of the previous CCNN model. Training of
the CCNN was significantly slower depending on the number of candidates per iteration
(model size is not a constraint for this problem with current hardware). Furthermore,
having a smaller number of nodes per layer constrains the breadth of features that can be
extracted. Finally, with the step-by-step weight freezing, it limits the identification of more
complex features as these can no longer influence shallower ones.
The problem, from the perspective of the network, is being treated as a multi-label
and multi-output task. For each of the potential labels of pneumonia (−/+) and COVID-19
(−/+), a binary output node is added to the network. The loss function used to minimize
for both cases is the binary cross entropy, in which the global goal is to minimize the sum of
the two. During training, two sets of weights are stored, those that result in the minimum
loss value individually for the labels. Following for the inference phase, the respective
weights are loaded to make the predictions.
The data were split to train (60%), validation (20%), and test (20%) sets. The dis-
tribution of cases of pneumonia and COVID-19 were balanced across the three datasets.
Additionally, for the training set, the data were expanded by switching the symmetrical
points of the left lung with the right and vice versa. A total of five experiments were
conducted with the available data, raw temperature, raw temperature, and metadata;
all aggregated pointwise metrics (AS, ASIN, SP, RI, Int, and Sk), raw temperature, and
pointwise metrics; and, finally, raw temperature, pointwise metrics, and metadata. After
the model is trained, the receiver operating characteristic is used with the validation data to
determine an optimal threshold for each output to balance the true and false positive rates.
The results of the experiments are summarized in Table 5. The overall best per-
formance was achieved when using the raw temperature readings and the aggregated
pointwise metrics. It achieved a sensitivity of 71.05% and specificity of 74.35%. The highest
sensitivity achieved, of 79.85%, was with using the temperature readings in conjunction
with the metadata. However, it obtained a sensitivity of 48.37%. In contrast, the highest
specificity, of 77.29%, was obtained using only the aggregated metrics. The sensitivity fell
at 50.99%.
We conducted a second iteration of experiments that were based on the raw tempera-
ture reading and the extracted metrics, as they were the best results thus far. Knowing that
whether a patient is wearing clothes or not during the recording can affect the results, we
prepared a second batch of experiments. While including all the metadata information had
a negative impact, we reran our network with adding only the clothes flag. Additionally,
we experimented with creating an ensemble model. One network was trained only with
data the patients were wearing their clothes and the other that they were not.
Diagnostics 2021, 11, 259 11 of 15
Table 5. Results from neural network on different inputs.
Experiment Sensitivity Specificity
Raw temperatures 71.05% 57.52%
Raw temperatures and metadata 79.85% 48.37%
Metrics 50.99% 77.29%
Raw temperatures and metrics 71.05% 74.35%
Raw temperatures, metadata, and metrics 70.95% 48.18%
The results of the second set of experiments are summarized in Table 6. Including
the flag helped to improve the results. The sensitivity increased from 71.05% to 76.47%.
With a smaller increase for the specificity, it changed from 74.35% to 76.47%. The ensemble
approach significantly reduced the specificity to 47.06%. This can be attributed to the fact
that each network was now trained on a smaller set of data. Specifically, there were more
similarities than dissimilarities between patients wearing or not wearing clothes.
Table 6. Results from neural network on including the clothes flag. The base input data is raw
temperatures and the set of computed metrics.
Experiment Sensitivity Specificity
Raw temperatures and metrics 71.05% 74.35%
Raw temperatures, metrics, and clothes flag 76.19% 76.47%
Raw temperatures and metrics (ensemble clothes on/off) 76.19% 47.06%
In general, the model had slightly better performance in correctly detecting presence
of pneumonia in comparison to COVID-19. However, more data will be required to
better capture the diversity and complexity of the cases and allow the model to effectively
generalize. This also extends to when the patient metadata/additional information is
included, in which not all information offers benefits to the classification. One value that
has a positive impact is the clothes flag as it directly contributes to temperature differences
captured at the skin.
4. Discussion
We aimed to investigate the performance of MWR to diagnose theCOVID-19 lung
complications. Most studies used CT results as positive or negative, often without a clear
definition of a positive CT. One large study reported a 97% sensitivity of chest CT for
COVID-19 diagnosis but with a poor specificity of 25% [32]. The actual clinical value
of a positive CT result to confirm, or negative test results, strongly depend on disease
progression [33]. In recent trials, the sensitivity of chest CT was insufficient to exclude
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which supports
the consensus statement that chest CT should not be used as a diagnostic test alone [34]. IR
scanners cannot measure the internal temperature of organs, only the skin temperature
can.
MWR aggregate metrics had good diagnostic performance for COVID-19 pneumonia
but could not replace RT-PCR as a diagnostic test. Therefore, we suggest using MWR as a
complementary tool in individuals with COVID-19 symptoms and for the early screening
of asymptomatic infections. There are no ideal diagnostic methods. In some cases, all the
symptoms show in the COVID-19 patient, but the PCR test is negative. CT images do not
show lung damage or CT images may be unavailable.
There are five major observations about measured skin and internal temperature
values [35–37], which we have confirmed in this study.
1. Individual data points are hardly informative, due to inaccuracies in measurements
and noise-induced randomness.
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2. The mean value has limited informativeness due to individual variations in metabolism,
conductivity of the tissues, and changes in the ambient temperature.
3. An increase or a decrease in a point relative to its neighbors might be informative
(so-called thermal heterogeneity).
4. An increase or a decrease in a point relative to the symmetric point on the body might
be informative (so-called thermal asymmetry).
5. An increase or a decrease in the microwave temperature value relative to the infrared
temperature value might be informative (so-called thermal convergence), especially
compared to its neighbors.
It is also very important to consider that this methodology will be readily accessible
to the Low Middle Income Countries, and that it is even more convenient to use at the
primary healthcare level. The primary healthcare is the first line of treatment for patients
worldwide, and they are the first point of contact for the patients. MWR could identify
early stage lung damage to help the doctors in their decision-making process for patients
with some COVID-19 symptoms.
Usually, COVID-19 progresses through several stages. From days 1–4 of the disease
progression, fever persists, as does the cough. Second, breathing difficulty begins on day 5.
It is especially likely to happen if the person has a preexisting condition or is older. The
third stage is from days 6–10 when the outcome could lead to hospitalization. MWR could
be used at these stages to identify high-risk patients and to adjust their therapy. MWR
usually fails when the covid+ patient has no symptom at all, or when the patients have
very high fever >38.5 ◦C. It is not practical to use MWR in intensive care units. Initial
MWR training is required, but the procedure itself is not complex and is similar to the skin
temperature measurements performed on different parts of the human body.
Our study showed that MWR+/MWR– lung damage predictions could be used for
screening and stratifying patients into six groups:
• Covid+, pneumonia+, MWR+, accident and emergency hospitalization; usually, the
patients are already hospitalized.
• Covid− or RT-PCR test not available, pneumonia+, MWR+ hospitalization; usually
the patients are already hospitalized.
• Covid− or RT-PCR test not available, pneumonia− (or CT test not available,), MWR+;
consultancy with a specialist, repeat or take PCR test; repeat, or take CT test and MWR
examination.
• Covid+, pneumonia−, MWR−, repeat MWR test; most likely it is asymptomatic
COVID-19, and no further action is required.
• Covid−, pneumonia+, MWR−, repeat PCR and MWR tests; usually, the patients are
already hospitalized.
• Covid−, pneumonia−, MWR−; no further action is required.
The test could preferably be done with the clothes off, but when it is not possible, thin
clothes are allowed. Further studies are being carried out by the support of the Kyrgyz
Government to validate this protocol. In the follow-up study, we collected more data and
training on the Deep Neural Network system to include measurable parameters from blood
tests (C-reactive protein) and SpO2 in order to improve MWR diagnostics power. MWR
could be used for early lung diagnosis more widely where access to CT/PCR is limited,
including but not limited to
• Nursery homes;
• Ships;
• Remote locations (highlands, islands, deserts);
• Boarder security;
• Detention centers.
Our study has some limitations. It was conducted in a time frame when high rates
of COVID-19 and a low prevalence of other viral pneumonia were occurring. A higher
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incidence of seasonal respiratory viral infections will likely decrease the specificity of MWR.
Healthy individuals were underrepresented in our dataset.
All three hypotheses were fully confirmed both in statistical and clinical aspects.
Hypothesis #1—according to five main signs of inflammation from the course of physiology
(rubor, tumor, dolor, calor, functio laesa), almost all of them are inherent in pneumonia,
whatever etiology it may be. In hypothesis #2, there is almost always a local difference.
In hypothesis #3—when examining healthy people, a deviation of 2 degrees is associated
with the thickness of the skin and the thickness of the clothes in which it came, and the
external temperature factor also affects.
We have been actively using this technique for 4 months in clinical practice and it is of
great benefit, we do not notice any obvious errors.
COVID-19 could damage the brain, heart, gut, and other organs. MWR is already
being used for the diagnosis of different diseases [19]. In the future, it could be used for the
full body scan, including the head (brain), wrist (cardiovascular), lung (respiratory), and
guts (GI) to assess organ damage and eliminate the risk of COVID-19 rehabilitation stage.
Our newly developed wearable MWR sensor could be used to monitor patients 24/7,
but further development is required [38].
5. Conclusions
This study suggests that MWR could be used for the diagnosis of COVID-19 pneumo-
nia. Since MWR is inexpensive, it could ease the financial burden for both the patients and
countries, especially in LMIC.
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